Epstein-Barr virus mRNA vaccine - Virogin Biotech
Alternative Names: EPV mRNA vaccine - Virogin BiotechLatest Information Update: 06 May 2024
At a glance
- Originator Virogin Biotech
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 22 Mar 2024 Early research in Cancer in Canada (Parenteral), prior to March 2024 (Virogin Biotech pipeline, March 2024)